
Please try another search
Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
Name | Age | Since | Title |
---|---|---|---|
James F. Young | 68 | 2010 | Independent Chairman of the Board |
Stanley Charles Erck | 73 | 2009 | President, CEO & Director |
David M. Mott | 56 | 2020 | Independent Director |
Gregg Huber Alton | 56 | 2020 | Independent Director |
Richard Huntington Douglas | 69 | 2010 | Independent Director |
Rachel K. King | 63 | 2018 | Independent Director |
Margaret G. McGlynn | 63 | 2020 | Independent Director |
Richard J. Rodgers | 55 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review